Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Refractory cancer pain and drug-related toxicity controlled by an implantable drug delivery system

Nature Clinical Practice Oncology volume 2, pages 329–330 (2005)Cite this article

Smith TJ et al. (2005) An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 16: 825–833

Pain is the most prevalent and debilitating symptom associated with cancer, and current best-practice management is ineffective in 14% of patients. The Cancer Pain Trial (1999–2001) aimed to address this issue by investigating the efficacy of an implantable drug delivery system (IDDS). Smith et al., of the IDDS Study Group, now present the long-term results of this multicenter, international trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Glossary

VISUAL ANALOG SCALE (VAS)

A line anchored by word descriptors (e.g. 'no pain' and 'very severe pain') used to assess a characteristic that ranges across a continuum of values

NCI COMMON TOXICITY CRITERIA

National Cancer Institute criteria for identifying treatment-related adverse events to facilitate the evaluation of new cancer therapies, treatment modalities, and supportive measures; now replaced by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v3

Rights and permissions

Reprints and permissions

About this article

Cite this article

Refractory cancer pain and drug-related toxicity controlled by an implantable drug delivery system. Nat Rev Clin Oncol 2, 329–330 (2005). https://doi.org/10.1038/ncponc0210

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0210

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing